Bifidobacterium Breve SHMB 8001 Alleviates DSS-Induced Colitis in Mice Via Modulating the Intestinal Barrier and Gut Microbiota.

2026-02
Journal of food science 91(2)

PubMed: 41645793
DOI: 10.1111/1750-3841.70903

Study Design

Population: mice following dextran sulfate sodium (DSS) challenge
Methods: Evaluated the efficacy of a novel human breast milk-derived probiotic strain, Bifidobacterium breve (B. breve) SHMB 8001, against colitis in mice following dextran sulfate sodium (DSS) challenge

Rigorous Journal

Microbial-based therapies, including probiotics, may provide complementary approaches for treating inflammatory bowel disease (IBD). Our research evaluated the efficacy of a novel human breast milk-derived probiotic strain, Bifidobacterium breve (B. breve) SHMB 8001, against colitis in mice following dextran sulfate sodium (DSS) challenge and elucidated its molecular basis. B. breve SHMB 8001 administration alleviated DSS-induced alterations in body mass, disease activity index (DAI), colon dimensions (p = 0.007), and tissue histology (p < 0.001). SHMB 8001 increased the colonic levels of critical barrier proteins MUC2 (p < 0.001), occludin (p < 0.001), and claudin-1 (p < 0.001), as measured by qPCR and western blotting. SHMB 8001 significantly elevated the levels of fecal short-chain fatty acids (SCFAs) and colonic G protein-coupled receptor (GPR) 43 (p = 0.023) and the percentage of CD4⁺ CD25⁺ FOXP3⁺ Treg cells (p = 0.009), as determined by gas chromatography-mass spectrometry (GC-MS), qPCR, and flow cytometry, respectively. Furthermore, qPCR revealed that SHMB 8001 up regulated the colonic expression of interleukin (IL)-10 (p = 0.010) but suppressed the expression of IL-1β (p = 0.013), IL-6 (p = 0.005), and tumor necrosis factor (TNF)-α (p = 0.021). High-throughput 16S rRNA gene sequencing revealed that SHMB 8001 modulated the composition of the gut micro biota by enriching bacterial genera capable of producing SCFAs, including Bifidobacterium, norank_f_Muribaculaceae, and Lactobacillus, and partially restored the microbial functional pathways altered by DSS. In conclusion, this study demonstrates that B. breve SHMB 8001 represents a potential probiotic strain for alleviating colitis by normalizing intestinal homeostasis. PRACTICAL APPLICATIONS: This research evaluated the efficacy of a novel human breast milk-derived probiotic strain, B. breve SHMB 8001, against colitis in mice following dextran sulfate sodium (DSS) challenge, and delineated its molecular basis. B. breve SHMB 8001 represents a potential probiotic strain for alleviating colitis via normalizing intestinal homeostasis.

Research Insights

Supplement	Dose	Health Outcome	Effect Type	Effect Size	Source
Bifidobacterium breve	—	Improved Intestinal Barrier Function	Beneficial	Large	View source SHMB 8001 increased the colonic levels of critical barrier proteins MUC2 (p < 0.001), occludin (p < 0.001), and claudin-1 (p < 0.001).
Bifidobacterium breve	—	Increased Regulatory T Cell Count	Beneficial	Moderate	View source the percentage of CD4+ CD25+ FOXP3+ Treg cells (p = 0.009), as determined by gas chromatography-mass spectrometry (GC-MS), qPCR, and flow cytometry, respectively.
Bifidobacterium breve	—	Increased Short-Chain Fatty Acid Production	Beneficial	Moderate	View source SHMB 8001 significantly elevated the levels of fecal short-chain fatty acids (SCFAs) and colonic G protein-coupled receptor (GPR) 43 (p = 0.023).
Bifidobacterium breve	—	Reduced Colitis Severity	Beneficial	Large	View source B. breve SHMB 8001 administration alleviated DSS-induced alterations in body mass, disease activity index (DAI), colon dimensions (p = 0.007), and tissue histology (p < 0.001).